Information intended for healthcare professionals only.
Guidelines identified a need for clinical guidance in a specific area and approached Mylan for an educational grant to support the development of a working party guideline. This working party guideline was developed by Guidelines, and the Chair and members of the group were chosen by and convened by ...
Information intended for healthcare professionals only. This formulary decision guide was developed from content supplied by Novo Nordisk in a format developed by Guidelines in Practice. It has been reviewed by Novo Nordisk, who commissioned the development of the formulary decision guide.
Watch this short animation, commissioned by Napp Pharmaceuticals Limited, to find out about the third joint consensus report on the management of hyperglycaemia in type 2 diabetes by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Related Guidelines summaries
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.
This summary provides recommendations on blood glucose targets, patient education, and includes a useful algorithm on blood glucose management
This comparison table summarises recommendations on the management of hyperglycaemia in adults with type 2 diabetes from ADA/EASD, NICE, and SIGN.
Summary covers glycaemic targets for older people, priorities for improving high-quality diabetes care, and a useful frailty assessment pathway.
Summary of NICE guidance on pancreatitis covers managing complications, nutrition support, and referral for specialist treatment.